Impact of sirolimus duration on hepatitis C related fibrosis progression in liver transplant recipients

American Journal of Transplantation

Volumn 12, Issue 5, 2012, Pages 1356-1357

  Kim, M ^a   Curry, M P ^b   Rogers, C C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Deaconess Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG WITHDRAWAL; FIBROSIS; GRAFT RECIPIENT; HEPATITIS C; LETTER; LIVER TRANSPLANTATION; PRIORITY JOURNAL;

FEMALE; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; MALE; SIROLIMUS;

EID: 84862794489     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03942.x     Document Type: Letter

References (2)

1. McKenna GJ, Trotter JF, Klintmalm E, et al,. Limiting Hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011; 11: 2379-2387.
2. Rogers C, Stevens D, Curry M,. Impact of conversion to sirolimus-based immunosuppression on fibrosis progression in HCV+Liver transplant recipients. Pharmacotherapy 2011; 31: 1044.